Medicine Description parkintreat-uae 1 mg
parkintreat 1mg 30 tablets - rosheta uae is a medication that contains rasagiline, a selective and irreversible inhibitor of monoamine oxidase B (MAO-B). By inhibiting MAO-B, rasagiline prevents the breakdown of dopamine in the brain, which is particularly beneficial for patients with Parkinson's disease, where dopamine levels are compromised. This mechanism enhances dopaminergic activity and helps alleviate the motor symptoms associated with Parkinson's disease. Rasagiline's effect not only aids in improving the quality of life for patients but also may offer neuroprotective properties that may slow disease progression.
Indications and Uses of parkintreat 1mg 30 tablets - rosheta uae
- Idiopathic Parkinson's disease
- Used as initial monotherapy in early-stage Parkinson's disease
- Serves as adjunct therapy with levodopa in advanced stages
- Improves key symptoms including tremor, bradykinesia, and muscle stiffness
Side Effects of parkintreat 1mg 30 tablets - rosheta uae
- Headache
- Dizziness
- Insomnia
- Nausea
- Abdominal pain
- Orthostatic hypotension
Storage and Handling
Store parkintreat tablets at room temperature, away from direct sunlight and moisture. Keep out of reach of children, and do not use after the expiration date printed on the packaging.
Patient Advice and Precautions
Patients should follow their healthcare provider's instructions carefully when using parkintreat. It's important to report any unusual side effects or changes in symptoms. Avoid consuming excessive amounts of tyramine-rich foods to reduce the risk of hypertensive crises. Regular follow-up appointments are essential to monitor the medication's effectiveness and adjust treatment as necessary.